New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events Read more about New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events
Amgen Announces Final Results Of Tender Offer Read more about Amgen Announces Final Results Of Tender Offer
Amgen Announces 2018 Second Quarter Dividend Read more about Amgen Announces 2018 Second Quarter Dividend
Amgen To Present At the Cowen and Company 38th Annual Health Care Conference Read more about Amgen To Present At the Cowen and Company 38th Annual Health Care Conference
Amgen Announces Preliminary Results Of Tender Offer Read more about Amgen Announces Preliminary Results Of Tender Offer
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta® (pegfilgrastim) Read more about Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta® (pegfilgrastim)
Amgen To Present New Data From Repatha® (evolocumab) Clinical Trials At ACC.18 Read more about Amgen To Present New Data From Repatha® (evolocumab) Clinical Trials At ACC.18
Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe Read more about Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab) Read more about Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)
Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology Read more about Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
